Potentiation of gemcitabine by Turmeric Force™ in pancreatic cancer cell lines

Oncology Reports

Volumn 23, Issue 6, 2010, Pages 1529-1535

  Ramachandran, Cheppail ^a   Resek, Anna P ^a   Escalon, Enrique ^a   Aviram, Anat ^a   Melnick, Steven J ^a  

^a MIAMI CHILDREN'S HOSPITAL   (United States)

Author keywords

Cytotoxicity; Gemcitabine; Pancreatic carcinoma; Synergism; Turmeric force

Indexed keywords

GEMCITABINE; GEMCITABINE PLUS TURMERIC FORCE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; STAT3 PROTEIN; TURMERIC; TURMERIC FORCE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CURCUMIN; CYCLOOXYGENASE 2; DEOXYCYTIDINE; MESSENGER RNA; STAT3 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; IMMUNOBLOTTING; METABOLISM; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; CYCLOOXYGENASE 2; DEOXYCYTIDINE; DRUG SYNERGISM; HUMANS; IMMUNOBLOTTING; INTERLEUKIN-8; NF-KAPPA B; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR;

EID: 77951746654     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000792     Document Type: Article

References (24)

1. Warshaw A and Fernandez-del Castillo C: Pancreatic carcinoma. N Engl J Med 326: 455-465, 1992.
2. Niedererhuber JE, Brennan MF and Melnick HR: The National Cancer Data Base report on pancreatic cancer. Cancer 76: 1671-1677, 1995.
3. Bouvet M, Binmoeller KF and Moossa AR: Diagnosis of adenocarcinoma of the pancreas. In: American Cancer Society Atlas of Clinical Oncology: Pancreatic Cancer. Cameron JL (ed). Canada BC Decker, Hamilton, Ontario, 2001.
4. Casper ES and Kelsen DP: Adenocarcinoma of the pancreas: overview of workup and management: Adv Oncol 11: 17-22, 1996.
5. Bharti AC and Aggarwal BB: Chemopreventive agents induce suppression of nuclear factor-κB leading to chemosensitization. Ann NY Acad Sci 973: 392-395, 2002.
6. Li Y, Ellis KL, Ali S, El-Rayes BF, Nedeljkovic-Kurepa A, Kucuk O, Philip PA and Sarkar FH: Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibiotor of NF-κB in BxPC-3 pancreatic cancer cell line. Pancreas 4: 90-95, 2004.
7. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J and Sarkar FH: Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 65: 9064-9072, 2005.
8. Dhillon N, Aggarwal BB, Li L, Wolff RA, Abbruzzese JL, Hong DS, Camacho LH, Ng C and Kurzrock R: Phase II trial of curcumin, an NF-κB in patients with advanced pancreatic cancer. Society for Integrative Oncology Third International Conference on Multidisciplinary advances in Integrative Oncology. Boston, MA. Abst #D025, 2006.
9. Dhir V and Mohandas KM: Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. Indian J Gastroenterol 18: 24-28, 1999.
10. Sharma RA, McLellan HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ and Steward WP: Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7: 1894-1900, 2001.
11. Anand P, Kunnumakkara AB, Newman RA, Newman RA and Aggarwal BB: Bioavailability of curcumin: problems and Promises. Mol Pharamaceut 4: 807-818, 2007.
12. 2M phase arrest and synergy with doxorubicin in human cancer cell lines. Proc 3rd SIO meeting. Boston, MA. Abstract #C014, 2006.
13. Ramachandran C, Nair PKR, Alamo A, Cochrane BC, Escalon E and Melnick SJ: Anticancer effects of amooranin in human colon carcinoma cell line in vitro and in nude mice xenografts. Int J Cancer 119: 2443-2454, 2006. (Pubitemid 44546970)
14. Chou TC and Talalay P: Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4: 450-454, 1983.
15. Ramachandran C, Khatib Z, Pefkarou A, Fort J, Fonseca HB, Melnick SJ and Escalon E: Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells. J Neurooncol 67: 19-28, 2004. (Pubitemid 38418245)
16. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V and Kurzrock R: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491-4499, 2008.
17. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M and Parulekar W: Erlotinib plus gemcitabine compared with gemctiabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007.
18. Philip PA, Benedetti J , Fenoglio-Preiser, C. Zalupski M, Lenz H, O'Reilly E, Wong R, Atkins J, Abruzzese J and Blanke C: Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study. Proc ASCO 25: 4509, 2007.
19. Chua YJ and Zalcberg JR: Pancreatic cancer - is the wall crumbling? Ann Oncol 19: 1224-1230, 2008.
20. Thomas SL, Zhong D, Zhou W, Malik S, Liotta D, Snyder JP, Hamel E and Giannakakou P: EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle 15: 2409-2417, 2008.
21. Subramaniam D, May R, Sureban SM, Lee KB, George R, Kuppusamy P, Ramanujam RP, Hideg K, Dieckgraefe BK, Houchen CW and Anant S: Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity. Cancer Res 68: 1962-1969, 2008.
22. Mosley CA, Liotta DC and Snyder JP: Highly active anticancer curcumin analogues. Adv Exp Med Biol 595: 77-103, 2007.
23. Ramachandran C, Sarkar M, Resek AP, Escalon E and Melnick SJ: Potentiation of chemotherapeutic drugs by curucmin in pancreatic cancer cells. J Soc Integr Oncol 6: 180, 2008.
24. Ramachandran C, Nair PKR, Escalon E and Melnick SJ: Comparative therapeutic and adjuvant effects of curcumin and turmeric force™ against human cancer. Anticancer Res 28: 3457, 2008.